Galecto, Inc. (“Galecto”) announces the completion of the acquisition of Damora Therapeutics, Inc. (“Damora”), a privately held biotechnology company advancing a pipeline of antibody therapeutics aimed at transforming the treatment of mutant calreticulin- (mutCALR)-driven Myeloproliferative Neoplasms (MPNs), including Essential Thrombocythemia (ET) and Myelofibrosis (MF). The acquisition gives the combined company a pipeline covering a broad spectrum of hematological cancers and leverages the deep expertise of both teams, and positions Galecto to advance Damora’s complementary assets for people living with blood cancers, with the goal of developing safer, more effective, and more convenient disease-modifying therapies.
Read the full article: Galecto Announces Acquisition of Damora Therapeutics //
Source: https://www.globenewswire.com/news-release/2025/11/10/3184348/0/en/Galecto-Announces-Acquisition-of-Damora-Therapeutics.html